2003
DOI: 10.1046/j.1525-1594.2003.07140.x
|View full text |Cite
|
Sign up to set email alerts
|

Bioartificial Liver Inoculated with Porcine Hepatocyte Spheroids for Treatment of Canine Acute Liver Failure Model

Abstract: The aim of this study was to evaluate a novel bioartificial system in a canine model of acute liver failure. An acute liver failure model in canines was induced by an end-side portocaval shunt combined with common bile duct ligation and transection. The bioartificial liver system, which utilized blood perfusion through a hollow fiber bioreactor from BIOLIV A3A inoculated with 1.0 - 3.1 x 1010 porcine hepatocyte spheroids, was developed for the treatment of acute liver failure. Sixteen acute liver failure model… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2004
2004
2021
2021

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 12 publications
(5 citation statements)
references
References 45 publications
0
5
0
Order By: Relevance
“…Hepatocyte transplantation may also be able to replace whole‐organ transplantation in the treatment of certain metabolic liver diseases (19). Many sources of hepatic cells have been proposed and investigated as an alternative to isolated human hepatocytes, such as human‐derived tumoral cell lines (20), immortalized human hepatocytes, (21, 22) porcine liver cells (23–25), etc. Each of these sources presents problems and relative contraindications to their clinical use including the risk of neoplastic transmission or transformation and biosafety for animal tissue.…”
Section: Discussionmentioning
confidence: 99%
“…Hepatocyte transplantation may also be able to replace whole‐organ transplantation in the treatment of certain metabolic liver diseases (19). Many sources of hepatic cells have been proposed and investigated as an alternative to isolated human hepatocytes, such as human‐derived tumoral cell lines (20), immortalized human hepatocytes, (21, 22) porcine liver cells (23–25), etc. Each of these sources presents problems and relative contraindications to their clinical use including the risk of neoplastic transmission or transformation and biosafety for animal tissue.…”
Section: Discussionmentioning
confidence: 99%
“…Many BAL systems have been tested, such as ELAD (Extracorporeal Liver Assist Devices) [183], BLSS (bioartificial liver support system) [184], and BIOLIV A3A [185]. Although considerable improvements have been made, BAL systems are still in early stages of development with countless challenges.…”
Section: Artificial Livermentioning
confidence: 99%
“…By applying capillary membrane technology that gives a dynamic and continuous perfusion, a physical active scaffold for cell aggregation is provided. The medium perfusion with the cells floating in the space between capillaries offer a system allowing the cells to grow with increased cell density closer to physiological levels (Chen et al, 2003). The hollow fiber reactors have been further developed to a special four‐compartment bioreactor developed by Gerlach et al (1994) and Zeilinger et al (2002), a highly sophisticated device for culturing of hepatocytes (Fig.…”
Section: Differentiation Of Hesc Into Functional Cell Typesmentioning
confidence: 99%